Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Fagron  /  Fagron November 2016

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Fagron BRU:FAGR.BL, BE0003874915

  • 17,600 19 apr 2024 17:35
  • -0,100 (-0,56%) Dagrange 17,500 - 17,660
  • 31.301 Gem. (3M) 53,6K

Fagron November 2016

247 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste | Omlaag ↓
  5. sappas 10 november 2016 17:04
    quote:

    moneymaker_BX schreef op 10 november 2016 17:00:

    De afstort is begonnen
    stap in de trein naar 4.50
    goede reis
    Is dat de trein van PostNL?

    Heb je niets anders te doen dan onzinnige niet onderbouwde postings te plaatsen.
    Dat doe je tot vervelends toe op heel wat forums

    Groetjes,

    Sappas
  8. Azoia 10 november 2016 19:36
    Perrigo Company Plc, a maker of generic and over-the-counter drugs, said on Thursday it would review strategic alternatives for the rights to the royalties from sales of its multiple sclerosis drug Tysabri.
    Perrigo also said it continued to expect full-year adjusted earnings per diluted share to be $6.85 to $7.15. Analysts on average were expecting an adjusted profit of $7.02, according to Thomson Reuters I/B/E/S.

    The company, which had a market capitalization of $11.97 billion (10 billion pounds) as of Wednesday's close, however, said it expected to report a net loss of $9.04 to $9.34 per diluted share for the calendar year 2016.

    Perrigo has been targeted by activist investor Starboard Value LP, saying the Dublin-based drugmaker must make immediate improvements to turn around its sagging stock price.

    The royalty divestment is one of the actions that Starboard called for earlier in September when it disclosed a 4.6 percent stake in the company and complained about its sagging stock price.

    Dublin-based Perrigo has hired Morgan Stanley as financial adviser to lead the review process for Tysabri, the company said in a statement.

    Perrigo had been exploring sale of Tysabri royalties before Starboard's proposals, Reuters reported in September citing people familiar with the matter. Royalty Pharma, a privately held company that specializes in acquiring drug royalties, is one of the potential buyers, the people had added.

    The company reported a net loss of $1.26 billion, or $8.76 per share, in the third quarter ended Oct. 1, compared with a profit of $113 million, or 77 cents per share, a year earlier.

    The quarterly net loss includes a goodwill impairment charge of $804 million and a brand intangible assets impairment charge of $866 million related to the Omega acquisition.

    On an adjusted basis, the company earned $1.80 per share, above the analysts' average estimate of $1.58, according to Thomson Reuters I/B/E/S.

    Perrigo's revenue rose 1 percent to $1.35 billion, which includes the sales of $22 million from held-for-sale units.

    Analysts on average were expecting revenue of $1.28 billion.

    Separately, the company said it appointed two independent members, Geoffrey Parker and Theodore Samuels, to its board.

    Current board members Michael Jandernoa and Gary Kunkle will not stand for reelection in 2017, the company added.
  9. Azoia 10 november 2016 19:37
    drops early head and neck cancer drug plans
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/10/2016 | 09:58am CET
    AstraZeneca (>> AstraZeneca plc) said on Thursday it had given up on the idea of seeking an early approval of its immunotherapy drug durvalumab in head and neck cancer using mid-stage Phase II clinical trials data.
    AstraZeneca (>> AstraZeneca plc) said on Thursday it had given up on the idea of seeking an early approval of its immunotherapy drug durvalumab in head and neck cancer using mid-stage Phase II clinical trials data.

    The move follows recent changes in the competitive landscape, which has seen Merck's (>> Merck & Co., Inc.) similar Keytruda approved for the condition, reducing the case for special regulatory treatment of durvalumab.

    The decision to drop early filing plans in head and neck cancer follows a similar outcome in lung cancer, where AstraZeneca was also too late because Keytruda and Bristol-Myers Squibb's (>> Bristol-Myers Squibb Co) Opdivo had already won approval.

    The drugmaker's main hopes for durvalumab, however, are unaffected, since its big potential lies in helping previously untreated lung cancer patients, where it has shown promise when given as part of a combination therapy.

    (Reporting by Ben Hirschler; editing by Jason Neely)
  11. aandeeltje! 11 november 2016 12:15
    Het kan natuurlijk nooit positief uitwerken als de mogelijke claims terecht worden teoegekend, ook al speelt het op aandeelhoudersniveau. Het is natuurlijk maar de vraag of de anerikanen niet hun werk hebben gedaan en hoe de contaracten in elkaar zitten. Als er echter helemaal niets van klopt en het bij voorbaat een groot lucht verhaal is en de aandeelhouders ook nog ergens voor in staan, tja dan kan dat toch gevolgen hebben. Klaarblijkelijk ziet de ander toch enige mogelijkheden.
  16. löngterm 14 november 2016 16:47
    Laatste tijd is het erg rustig omtrent dit aandeel.
    Van mij mag er wel wat meer actie in zitten ;)
    Hopen dat Trump binnenkort een leuk woordje houdt waar de gezondheid zorg in voorbij komt.

    Zeker nu hij heeft aangegeven Obama care grotendeels intact te laten en geen restrictie op medicijnen wil zetten zoals Clinton voorstelde ziet het er naar mijn idee dubbel positief uit. Koers reactie op dit nieuws lijkt echter achter te blijven dus ben benieuwd wanneer er een grote speech gaat komen.
  17. Azoia 14 november 2016 19:55
    Johnson : Study Suggests Heart-Disease Patients May Need Fewer Blood Thinners
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/14/2016 | 07:13pm CET
    By Ron Winslow
    NEW ORLEANS -- Researchers said a study involving reduced doses of Johnson & Johnson's anticoagulant Xarelto suggests it may be possible for patients with two types of heart disease to avoid the need for three different blood thinners to protect them from stroke and heart attack.

    Between one million and two million patients in the U.S. and Europe suffer from both a heart rhythm disorder called atrial fibrillation and blockages in their coronary arteries that are propped open with stents to alleviate chest pain.

    Currently, such patients often get a total of three different medicines -- aspirin and a drug called clopidogrel to keep heart-attack causing clots from forming in stents, and either warfarin or a new anticoagulant such as Xarelto to prevent stroke-causing clots in atrial fibrillation. Each drug hits a different target involved in formation of blood clots.

    But so much blood-thinning causes more than 25% of patients to suffer major and even potentially life-threatening bleeding episodes.

    "The concern this causes for patients is very big," said Michael Gibson, a cardiologist at Harvard-affiliated Beth Israel Deaconess Medical Center, Boston, and principal investigator of the new trial.

    The new, 2,100-patient study found that 16.8% patients treated with a two-drug regimen -- 15 milligrams of Xarelto plus clopidogrel -- suffered what researchers termed clinically significant bleeding events, compared with 26.7% of patients treated with warfarin, clopidogrel and aspirin. That amounts to a 41% reduction in risk of such bleeding.

    Dr. Gibson said 18% of a third group of patients treated with a three-drug regimen -- 2.5 milligrams of Xarelto plus clopidogrel and aspirin -- suffered significant bleeding events.

    The study also found that 5.6% of patients in the warfarin-treated group suffered a heart related death, heart attack or stroke, compared with 6% given 2.5 milligrams of Xarelto and 6.5% for those with the two-drug regimen including 15 milligrams of Xarelto. But the number of such events in the study was too small to enable researchers to conclude with confidence that the reduce blood thinning regimens didn't put patients at higher risk of heart attacks and strokes.

    Dr. Gibson presented the data at the annual scientific meeting of the American Heart Association. The results also were published in separate papers in the New England Journal of Medicine and the journal Circulation.

    "We've hated to put patients on triple therapy," said Vincent Bufalino, a cardiologist at Advocate Health Care, Oakland Terrace, Ill., who wasn't involved with the study. He said doctors are already treating some patients with just two drugs, generally dropping aspirin and using clopidogrel and either warfarin or a drug like Xarelto.

    The study "makes us feel better about what we've been shifting towards," he said.

    Gabriel Steg, a cardiologist at Hopital Bichat, Paris, said a previous, smaller study using a two-drug of warfarin and clopidogrel (and no aspirin) in stent patients who also have atrial fibrillation was effective in reducing bleeding. Though warfarin is a difficult drug to use, that regimen would be cheaper than ones involving Xarelto, he noted.

    Write to Ron Winslow at ron.winslow@wsj.com
  18. Azoia 14 november 2016 19:58
    Suggests Celebrex Isn't Riskier Than Rival Pain Drugs
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/14/2016 | 08:17am CET
    By Ron Winslow
    NEW ORLEANS--A study of arthritis drugs found that, contrary to common belief, Pfizer Inc.'s painkiller Celebrex posed no higher risk to a patient's heart than ibuprofen or naproxen, two widely used rivals.

    Patients assigned to take Celebrex suffered numerically fewer heart-related deaths, heart attacks and strokes than those assigned to either of the other drugs, according to two different analyses of the 24,000-patient study.

    But limitations of the data led some researchers to question the results.

    The three drugs are among more than two dozen medicines known as nonsteroidal anti-inflammatory drugs, or NSAIDs, that account for some 100 million prescriptions in the U.S. each year.

    Doctors said the results provide reassurance to patients taking moderate doses of Celebrex after more than a decade of controversy over the heart-related safety of a class of NSAIDs called COX-2 inhibitors. The concern was triggered in 2004 when Merck & Co. was forced to pull its COX-2 drug Vioxx from the market after a study linked it to increased risk of a heart attack.

    Pfizer withdrew a second COX-2 at the time but was permitted to continue marketing Celebrex provided it conduct what became the current study to assess its effect on heart risk. The Vioxx link had persuaded many doctors that Celebrex--now commonly available as generic celecoxib--carried a higher heart risk than naproxen and other NSAIDs.

    The result of the study "is exactly opposite of what everybody thought it would be," said Steven E. Nissen, chief of cardiovascular medicine at the Cleveland Clinic and principal investigator of the study. The study also didn't find any evidence to support the belief that naproxen is safer for the heart than other NSAIDs, he said.

    He presented the findings Sunday at the annual scientific meeting of the American Heart Association. They were also published online by the New England Journal of Medicine.

    The Vioxx episode ultimately led the U.S. Food and Drug Administration to mandate that all NSAIDs carry a warning about their potential for increasing risk of serious cardiovascular events. That includes Aleve, an over-the-counter version of naproxen, and Motrin and Advil, OTC versions of ibuprofen. (Celecoxib isn't available in a nonprescription version.)

    Commenting on the latest findings, cardiologist Richard Chazal said, "For my patients on celecoxib, the study makes me a little more comfortable that I'm not exposing them to a greater risk." Dr. Chazal practices in Fort Myers, Fla., and is president of the American College of Cardiology. He wasn't involved in the study.

    The trial has important limitations. More than two-thirds of the participants stopped taking their assigned drug during the study and 27% were lost to follow-up, lending uncertainty to the findings.

    Some researchers said certain features of the trial could have skewed the outcome in favor of Celebrex. For instance, aspirin is commonly taken by patients to reduce heart risk, but its potential benefit could be blocked if patients also take either naproxen or ibuprofen, an effect that would favor Celebrex, said Elliott Antman, a cardiologist at Brigham and Women's Hospital in Boston. The study didn't account for how patients took aspirin during the study.

    He also said doctors treating U.S. patients in the study were precluded by FDA restrictions from prescribing Celebrex at higher than 200 milligrams a day while they could give patients assigned to the other drugs comparably higher doses to relieve persistent pain. Celebrex patients may not have taken high enough doses to trigger cardiac concerns, he suggested.

    "I was not surprised by these data," Dr. Antman said. "I personally don't think it's going to change how I practice."

    Dr. Nissen acknowledged the study's limitations but called dose level worries "a red herring." Using a pain scale, the study found "no clinically meaningful differences in pain relief," he said. That would suggest doses were sufficient to compare the drugs' adverse effects.

    Beyond the primary finding of what doctors call "noninferiority" of the three drugs for heart related risk, Dr. Nissen and his colleagues found in secondary analyses that Celebrex actually was safer than naproxen and ibuprofen on measures of ulcers and other gastrointestinal side effects, and safer than ibuprofen on kidney complications.

    The study enrolled patients with either osteoarthritis or rheumatoid arthritis who needed to take NSAIDs daily to function. They were given doses of drugs commonly used in medical practice. Dr. Nissen said he considers the non-inferiority finding as "rock solid."

    Dr. Nissen and others cautioned that all NSAIDs can harm the heart, especially for patients already diagnosed with heart disease or considered at serious risk.

    Dr. Nissen said the new study doesn't apply to people who occasionally take one of the lower-dose OTC versions of those medicines to treat an ankle sprain or a headache.

    But doctors warned that patients who double or triple up doses of such pills for prolonged periods could be at risk. Anyone taking any NSAID, he said, should "take the lowest dose you can for the shortest time you can."

    Write to Ron Winslow at ron.winslow@wsj.com
  20. Peter Markus 15 november 2016 09:41
    Fagron is zo n aandeel dat uit het niets 7% tot 10% kan stijgen.
    De afgelopen weken werd de koers bepaald door particulieren die wat kleingeld nodig hebben voor de dagelijkse beslommeringen en een paar gelukzoekers die daytraden.
    Grote partijen weten wel beter en blijven boven op hun aandelen zitten.
    Het zal niet lang meer duren en we zitten weer boven de 10.
    PM
247 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Indrukwekkende groei bij Fagron

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Fagron Nieuws

  1. 12 apr Beursblik: Berenberg verlaagt koersdoel Fagron licht
  2. 11 apr Kepler Cheuvreux: 'Fagron overtreft verwachtingen'
  3. 11 apr AEX gaat vlakke opening tegemoet, zorgt Christine Lagarde voor tumult? 7
  4. 11 apr Recordomzet voor Fagron
  5. 10 apr Beursblik: meer groei verwacht bij Fagron
  6. 29 mrt Beursblik: meer omzet voor Fagron verwacht
  7. 19 mrt Mawer Investment vergroot belang in Fagron
  8. 19 mrt Beursblik: overname Ceban slecht nieuws voor Fagron
  9. 21 feb Beursblik: ING verhoogt koersdoel Fagron
  10. 19 feb Koersdoelverhogingen KBC en Kepler voor Fagron

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!